KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

ClearPoint Neuro (CLPT) Raw Materials (2024 - 2026)

ClearPoint Neuro's Raw Materials history spans 2 years, with the latest figure at $7.1 million for Q4 2025.

On a quarterly basis, Raw Materials rose 28.15% to $7.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.1 million, a 28.15% increase, with the full-year FY2025 number at $7.1 million, up 28.15% from a year prior.
Raw Materials hit $7.1 million in Q4 2025 for ClearPoint Neuro, up from $6.1 million in the prior quarter.
Over the last five years, Raw Materials for CLPT hit a ceiling of $7.1 million in Q4 2025 and a floor of $5.5 million in Q4 2024.